Advate / Rixubis - direct healthcare professional communication (DHPC)

octocog alfa / Factor VIII Inhibitor Bypassing Activity / nonacog gamma

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Replacement BAXJECT II / BAXJECT II Hi-Flow Reconstitution Devices co-packaged with Advate/Feiba/Rixubis

Adopted

Key facts

• Medicine name:
  • Advate
  • Rixubis
• Active substance:
  • octocog alfa
  • Factor VIII Inhibitor Bypassing Activity
  • nonacog gamma
• Regulatory outcome:
  Variation
• DHPC type:
  Quality defect
• Dissemination date:
  14/08/2023